Merck & Co., Inc.

Merck & Co., Inc.

Merck & Co., Inc.

Overview
Date Founded

1891

Headquarters

2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA

Type of Company

Public

Employees (Worldwide)

69K

Industries

Pharmaceuticals
Medical Support Services
Wholesale: Consumer Non-Durables/Sundries
Hospitals & Patient Services
Biotechnology

Company Description

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Website
Contact Data
Trying to get in touch with decision makers at Merck & Co., Inc.? Subscribe today to access their professional contact information.
Executives & Employees

Chief Executive Officer

Executive Vice President, Global Services & Chief Financial Officer

Executive Vice President & General Counsel

Executive Vice President & President, Merck Research Laboratories

Senior Vice President, Finance, Global Controller & Principal Accounting Officer

Managing Director-BioPharma Business, China

Executive Vice President, Human Resources

Executive Vice President & President, Global Human Health

Executive Vice President & President, Merck Animal Health

Executive Vice President & President, Merck Manufacturing Division

Board of Directors

Chief Executive Officer at Corning, Inc.

Executive Chairman at 3M Company

President & Chief Executive Officer at Memorial Sloan-Kettering Cancer Center

Former Managing Partner of Global Business Operations at Accenture PLC

Chairman & Chief Executive Officer at SARR Group LLC

Professional at Communitas Capital Partners LLC

Senior Advisor at RRE Advisors LLC

President & Chief Executive Officer at The Mayo Clinic

Director of Biofrontiers Institute at The University of Colorado

Paths to Merck & Co., Inc.
Potential Connections via
Relationship Science
You
Merck & Co., Inc.
Owners & Shareholders
Details Hidden

SSgA Funds Management (SSgA FM) uses quantitative methods, as well as an industry-specific bottom-up investment approach to select stocks. The firm's mutual funds and institutional portfolios follow the same management style. They offer a broad range of strategies including: Active, Enhanced, and Passive Equity; Active & Passive Debt; Cash Management; Multi-Asset Class Solutions; Real Estate (including Direct Real Estate); Senior Loans; Managed Futures; and Private Equity. cash and real estate. ^The firm's Active, Enhanced & Passive are designed to outperform relative to benchmarks while maintaining appropriate risk exposure. Active equity strategies include enhanced equity and active quantitative strategies. The strategies cover market-cap and style segments of the market including: large-cap core, large-cap growth, large-cap value, mid-cap, small-cap, small-cap value, all-cap, and long-short equity. They also manage long-short and long-short market neutral strategies.SSgA FM's Active & Passive Debt strategies seek to meet clients’ objectives by controlling risk, while diversifying sources of excess return. The firm offers a range of investment styles from passive to active, short to long duration, tax-exempt, sovereign to high yield, and single country to global. The strategies typically use a stratified sampling methodology to build portfolios with the same characteristics as the index using quantitative and fundamental methods.^SSgA FM's cash strategies seek to generate current income while preserving capital and liquidity by investing in diversified portfolios of short-term securities.SSgA FM's Multi-Asset Class strategies employ an asset allocation model as means of diversification and seeks to position assets among major investment categories. The goal is to manage risk and enhance returns.SSgA FM is an advisor to funds that employ both passive and actively managed REITs investing strategies. They also offer direct real estate investment strategies.SSgA FM is an advisor to a fund that employs senior loan investing strategies. An unaffiliated sub-advisor directs the investments of the fund. SSgA FM's Managed Futures strategy allocates assets using two approaches: a managed futures strategy and a fixed income strategy. The managed futures strategy seeks to capture returns tied to global macroeconomic trends in the commodity futures markets, taking both long and short positions. The fixed income strategy is designed to generate interest income and capital appreciation to add diversification to the returns generated by the managed futures strategy.SSgA FM's Private Equity strategies focus on rigorous partner selection, thorough evaluation of quality investment opportunities, and fundamental, research-driven research. The strategies make direct or co-investments across sectors, as well as fund investments.

Details Hidden

Capital World Investors (CWI) employs a long-term, value-oriented global investment approach and a multiple portfolio manager system that combines teamwork and individual accountability. The firm is committed to maintaining low operating expenses, among the lowest in the fund industry. They utilize fundamental research to gather in-depth information on markets and companies around the world.CWI employs a security-by-security approach to portfolio construction and emphasize long-term investments. Their strategies focus on determining the difference between the fundamental value of a company and its price in the marketplace.CWI offers a wide variety of equity, fixed-income and balanced investment strategies. Their strategies are categorized as global, multi-regional and regional investment strategies.

Details Hidden

Wellington Management Co.'s investment approach is based on proprietary research. The firm's specialized portfolio management teams utilize in-house research to invest according to the investment philosophy, objective and process of each specific strategy. Portfolios are actively-managed based on the weight of the industry in the benchmark and using the best ideas from the firm's coverage universe. Wellington's investment strategies combine the use of fundamental research with quantitative valuation techniques.Wellington's equity and fixed-income investment selections are supported by global industry, regional and macroeconomic experts. Quantitative, technical, style and specialty research teams also contribute to the firm's equity investment processes. Wellington's fixed-income investment approach is based on credit, sovereign, quantitative and sector-based analysis. They seek to ensure that bottom-up investment decisions are made by also considering relevant top-down factors, and vice-versa.Wellington manages both regional and multi-currency multi-sector portfolios. Portfolios cover the duration spectrum from money market and short-term bonds to intermediate and market duration, core and core bond plus portfolios. The firm also invests in specific sectors including high yield, corporate, mortgage-backed, emerging markets and municipal bond portfolios.

Recent Transactions
Details Hidden

Merck & Co., Inc., Merck Sharp & Dohme (Holdings) Pty. Ltd. purchase Viralytics Ltd.

Details Hidden

HCL Technologies Ltd. purchases Telerx Marketing, Inc. from Merck & Co., Inc.

Details Hidden

Merck & Co., Inc., The StayWell Co. LLC purchase Provata Health, Inc.

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Accountant

Advised onMerck & Co., Inc. purchases Rosetta Inpharmatics LLC

Public Relations

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Legal Advisor

Advised onMerck & Co., Inc. purchases Schering-Plough Corporation

Advisors & Consultants
Legal Advisor

Secretary, Senior Vice President & General Counsel at General Electric Company

Advisor

Chairman at The Stagwell Group LLC

Legal Advisor

Partner at Jones Day

Clients

McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded on in 1984 and is headquartered in Dublin, Ireland.

Co-Founder at Caribou Biosciences, Inc.

Key Stats and Financials As of 2017
Market Capitalization
$169B
Total Enterprise Value
$171B
Earnings Per Share
$0.87
Revenue
$40B
Net Profit
$2.39B
Enterprise Value Sales
4.27x
Enterprise Value EBITDAOperating
13.51x
TEVNet Income
71.33x
Debt TEV
0.14x
EBITDAMargin
31.61%
Total Debt
$24.4B
Total Equity
$34.6B
EBITDA
$12.6B
Three Year Compounded Annual Growth Rate Of Revenue
-1.71%
Five Year Compounded Annual Growth Rate Of Revenue
-3.33%
Non-Profit Donations & Grants
$1M
2016
$100K +
2015
Political Donations
$1,000
2014
$1,000
2014
$500
2014
Investments
Details Hidden

Just Biotherapeutics, Inc. operates as biotechnology firm. Its products include biosimilars and novel and repositioned biologics. It also offers molecular design services; process and product platform services; and manufacturing and plant design services. The company was founded by James N. Thomas, Victor P. Fung, Dean K. Pettit, and Yining Zhao in 2014 and is headquartered in Seattle, WA.

Details Hidden

Moderna Therapeutics, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Details Hidden

Serimmune, Inc. develops diagnostics and therapeutics for autoimmune diseases. Its ImmuneIT platform provides composition of functional immune repertoires, creating new opportunities for therapeutic and diagnostic development. The company was founded by Patrick S. Daugherty and is headquartered in Santa Barbara, CA.

Investors
Details Hidden

Investor at Avid Radiopharmaceuticals, Inc.

Details Hidden

Chairman & Chief Executive Officer at OPKO Health, Inc.

Suppliers
Sodexo SA Other Business & Consulting Services | Issy-les-Moulineaux, IF

Sodexo SA engages in the provision of on-site services, benefits and rewards services, and personal and home care services. It offers integrated solutions which cover a variety of working and living environments and are available in client segments which include corporate, health care, education, defense, remote sites, justice services, seniors, and sports and leisure. Sodexo was founded by Pierre Bellon in 1966 and is headquartered in Issy-les-Moulineaux, France.

Model N, Inc. IT Consulting & Services | Redwood City, CA

Model N, Inc. engages in the provision of revenue management cloud solutions for the life science and technology industries. It solutions include two complementary suites of software applications: Revenue Management Enterprise and Revenue Management Intelligence. The Revenue Management Enterprise suite serves as the system of record for and automates the execution of revenue management processes such as pricing, contracting and incentive & rebate management. The Revenue Management Intelligence suite provides analytical insights to define and optimize revenue management strategies. Each of these suites consists of a number of applications, which can be purchased together or as separate stand-alone applications. The company was founded by Yarden Malka, Zack Rinat and Ali Tore on December 14, 1999 and is headquartered in Redwood Shores, CA.

Codexis, Inc. Chemicals | Redwood City, CA

Codexis, Inc. engages in the discovery, development, and sale of proteins. It offers enzyme optimization services and developing biocatalyst products. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Pfizer, Inc. Pharmaceuticals - WASHINGTON, DC

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Amgen, Inc. Biotechnology - Wilmington, DE

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Awards & Honors
Rank #72
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #72
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine